These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

69 related items for PubMed ID: 6652370

  • 1. The effect of p-chloromercuribenzoate on structure-binding relationships of muscarinic receptors in the rat cerebral cortex.
    Birdsall NJ, Burgen AS, Hulme EC, Wong EH.
    Br J Pharmacol; 1983 Sep; 80(1):197-204. PubMed ID: 6652370
    [Abstract] [Full Text] [Related]

  • 2. The effects of p-chloromercuribenzoate on muscarinic receptors in the cerebral cortex.
    Birdsall NJ, Burgen AS, Hulme EC, Wong EH.
    Br J Pharmacol; 1983 Sep; 80(1):187-96. PubMed ID: 6652369
    [Abstract] [Full Text] [Related]

  • 3. The effect of sulphydryl block on the binding of H1-antagonists to the muscarinic receptor.
    Burgen AS, Harbird CJ.
    Br J Pharmacol; 1983 Dec; 80(4):600-1. PubMed ID: 6152826
    [Abstract] [Full Text] [Related]

  • 4. Pharmacological differences between the high-affinity muscarinic agonist binding states of the rat heart and cerebral cortex labeled with (+)-[3H]cismethyldioxolane.
    Vickroy TW, Roeske WR, Yamamura HI.
    J Pharmacol Exp Ther; 1984 Jun; 229(3):747-55. PubMed ID: 6202869
    [Abstract] [Full Text] [Related]

  • 5. Binding of [3H]-pilocarpine to membranes from rat cerebral cortex.
    Hedlund B, Bartfai T.
    Naunyn Schmiedebergs Arch Pharmacol; 1981 Sep; 317(2):126-30. PubMed ID: 7300915
    [Abstract] [Full Text] [Related]

  • 6. Muscarinic receptor heterogeneity in rat central nervous system. II. Brain receptors labeled by [3H]oxotremorine-M correspond to heterogeneous M2 receptors with very high affinity for agonists.
    Gillard M, Waelbroeck M, Christophe J.
    Mol Pharmacol; 1987 Jul; 32(1):100-8. PubMed ID: 3600611
    [Abstract] [Full Text] [Related]

  • 7. Gallamine binding to muscarinic M1 and M2 receptors, studied by inhibition of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to rat brain membranes.
    Burke RE.
    Mol Pharmacol; 1986 Jul; 30(1):58-68. PubMed ID: 3755217
    [Abstract] [Full Text] [Related]

  • 8. On the involvement of multiple muscarinic receptor subtypes in the activation of phosphoinositide metabolism in rat cerebral cortex.
    Forray C, el-Fakahany EE.
    Mol Pharmacol; 1990 Jun; 37(6):893-902. PubMed ID: 2163015
    [Abstract] [Full Text] [Related]

  • 9. Influence of tissue integrity on pharmacological phenotypes of muscarinic acetylcholine receptors in the rat cerebral cortex.
    Md Anisuzzaman AS, Nishimune A, Yoshiki H, Uwada J, Muramatsu I.
    J Pharmacol Exp Ther; 2011 Oct; 339(1):186-93. PubMed ID: 21719469
    [Abstract] [Full Text] [Related]

  • 10. [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. I. Characterization and regulation of agonist binding to putative muscarinic subtypes.
    Watson M, Yamamura HI, Roeske WR.
    J Pharmacol Exp Ther; 1986 May; 237(2):411-8. PubMed ID: 3754580
    [Abstract] [Full Text] [Related]

  • 11. Modulation of the structure-binding relationships of antagonists for muscarinic acetylcholine receptor subtypes.
    Pedder EK, Eveleigh P, Poyner D, Hulme EC, Birdsall NJ.
    Br J Pharmacol; 1991 Jun; 103(2):1561-7. PubMed ID: 1884110
    [Abstract] [Full Text] [Related]

  • 12. Effects of (+/-)-huprine Y and (+/-)-huprine Z, two new anticholinesterasic drugs, on muscarinic receptors.
    Alcalá MM, Maderuelo A, Vivas NM, Camps P, Muñoz-Torrero D, Clos MV, Badia A.
    Neurosci Lett; 2005 May 06; 379(2):106-9. PubMed ID: 15823425
    [Abstract] [Full Text] [Related]

  • 13. Agonist binding to multiple muscarinic receptors.
    Vickroy TW, Watson M, Yamamura HI, Roeske WR.
    Fed Proc; 1984 Oct 06; 43(13):2785-90. PubMed ID: 6383872
    [Abstract] [Full Text] [Related]

  • 14. L-689,660, a novel cholinomimetic with functional selectivity for M1 and M3 muscarinic receptors.
    Hargreaves RJ, McKnight AT, Scholey K, Newberry NR, Street LJ, Hutson PH, Semark JE, Harley EA, Patel S, Freedman SB.
    Br J Pharmacol; 1992 Oct 06; 107(2):494-501. PubMed ID: 1422595
    [Abstract] [Full Text] [Related]

  • 15. On the muscarinic receptors in the urinary bladder and the putative subclassification of muscarinic receptors.
    Nilvebrant L.
    Acta Pharmacol Toxicol (Copenh); 1986 Oct 06; 59 Suppl 1():1-45. PubMed ID: 3524114
    [Abstract] [Full Text] [Related]

  • 16. Solubilization and characterization of high and low affinity pirenzepine binding sites from rat cerebral cortex.
    Berrie CP, Birdsall NJ, Hulme EC, Keen M, Stockton JM.
    Br J Pharmacol; 1985 Jul 06; 85(3):697-703. PubMed ID: 4027484
    [Abstract] [Full Text] [Related]

  • 17. Temperature coefficients of affinity constants for the binding of antagonists to muscarinic receptors in the rat cerebral cortex.
    Barlow RB, Birdsall NJ, Hulme EC.
    Br J Pharmacol; 1979 Aug 06; 66(4):587-90. PubMed ID: 465896
    [Abstract] [Full Text] [Related]

  • 18. Role of dopamine D1 receptors in the striatal and cortical fos expression induced by the muscarinic agonist pilocarpine.
    Wirtshafter D.
    Eur J Pharmacol; 2004 Mar 19; 488(1-3):85-90. PubMed ID: 15044039
    [Abstract] [Full Text] [Related]

  • 19. Functional and binding studies with muscarinic M2-subtype selective antagonists.
    Lazareno S, Roberts FF.
    Br J Pharmacol; 1989 Sep 19; 98(1):309-17. PubMed ID: 2804551
    [Abstract] [Full Text] [Related]

  • 20. Identification and characterization of muscarinic receptors potentiating the stimulation of adenylyl cyclase activity by corticotropin-releasing hormone in membranes of rat frontal cortex.
    Onali P, Olianas MC.
    J Pharmacol Exp Ther; 1998 Aug 19; 286(2):753-9. PubMed ID: 9694930
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.